Skip to Main Content

Paper Details

A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).
Cancer
32
2018
Author NameAffiliation
Elizabeth FoxChildren's Hospital of Philadelphia
Stuart L GoldsteinCancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati
  • 1 - 2

Datasets

Release 1.2